法布里病的酶替代疗法：阿加糖酶α与阿加糖酶β的比较 - Suppr

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.

作者信息

Mehta Atul, Beck Michael, Kampmann Christoph, Frustaci Andrea, Germain Dominique P, Pastores Gregory M, Sunder-Plassmann Gere

出版信息

Mol Genet Metab. 2008 Sep-Oct;95(1-2):114-5. doi: 10.1016/j.ymgme.2008.07.002. Epub 2008 Aug 12.

DOI:10.1016/j.ymgme.2008.07.002

PMID:18701330

Abstract

摘要

相似文献

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.

Mol Genet Metab. 2008 Sep-Oct;95(1-2):114-5. doi: 10.1016/j.ymgme.2008.07.002. Epub 2008 Aug 12.

Treatment with agalsidase beta during pregnancy in Fabry disease.

J Obstet Gynaecol Res. 2010 Apr;36(2):428-9. doi: 10.1111/j.1447-0756.2009.01164.x.

Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.

Iran J Kidney Dis. 2015 Sep;9(5):406-8.

Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.

Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):92-3. doi: 10.1016/j.ejogrb.2009.01.007. Epub 2009 Feb 23.

New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage.

Clin Genet. 2023 Mar;103(3):371-376. doi: 10.1111/cge.14266. Epub 2022 Nov 22.

Agalsidase alfa: specific treatment for Fabry disease.

Hosp Med. 2002 Jun;63(6):347-50. doi: 10.12968/hosp.2002.63.6.2005.

The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.

Expert Opin Biol Ther. 2009 May;9(5):631-9. doi: 10.1517/14712590902902296.

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice.

J Hum Genet. 2006;51(3):180-188. doi: 10.1007/s10038-005-0342-9. Epub 2005 Dec 22.

Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.

Int J Clin Pract. 2007 Jul;61(7):1234-5; author reply 1235. doi: 10.1111/j.1742-1241.2007.01399.x.

Spotlight on agalsidase beta in Fabry disease.

BioDrugs. 2007;21(4):269-71. doi: 10.2165/00063030-200721040-00007.

引用本文的文献

Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down-Regulation of Mannose-6-Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy.

J Am Heart Assoc. 2025 Feb 18;14(4):e036815. doi: 10.1161/JAHA.124.036815. Epub 2025 Feb 8.

Fabry disease: A pharmacological chaperone on the horizon.

Nat Rev Nephrol. 2016 Nov;12(11):653-654. doi: 10.1038/nrneph.2016.138. Epub 2016 Sep 26.

Fabry disease, enzyme replacement therapy and the significance of antibody responses.

J Inherit Metab Dis. 2012 Mar;35(2):227-43. doi: 10.1007/s10545-011-9400-y. Epub 2011 Oct 25.

Fabry disease.

Orphanet J Rare Dis. 2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30.

Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

J Control Release. 2011 Feb 10;149(3):323-31. doi: 10.1016/j.jconrel.2010.10.031. Epub 2010 Nov 1.

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Biologics. 2008 Dec;2(4):823-43. doi: 10.2147/btt.s3770.

Medical bioremediation of age-related diseases.

Microb Cell Fact. 2009 Apr 9;8:21. doi: 10.1186/1475-2859-8-21.

Fabry disease in children and the effects of enzyme replacement treatment.

Eur J Pediatr. 2009 Nov;168(11):1355-63. doi: 10.1007/s00431-009-0937-9. Epub 2009 Feb 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.

Mol Genet Metab. 2008 Sep-Oct;95(1-2):114-5. doi: 10.1016/j.ymgme.2008.07.002. Epub 2008 Aug 12.

Treatment with agalsidase beta during pregnancy in Fabry disease.

J Obstet Gynaecol Res. 2010 Apr;36(2):428-9. doi: 10.1111/j.1447-0756.2009.01164.x.

Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.

Iran J Kidney Dis. 2015 Sep;9(5):406-8.

Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.

Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):92-3. doi: 10.1016/j.ejogrb.2009.01.007. Epub 2009 Feb 23.

New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage.

Clin Genet. 2023 Mar;103(3):371-376. doi: 10.1111/cge.14266. Epub 2022 Nov 22.

Agalsidase alfa: specific treatment for Fabry disease.

Hosp Med. 2002 Jun;63(6):347-50. doi: 10.12968/hosp.2002.63.6.2005.

The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.

Expert Opin Biol Ther. 2009 May;9(5):631-9. doi: 10.1517/14712590902902296.

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice.

J Hum Genet. 2006;51(3):180-188. doi: 10.1007/s10038-005-0342-9. Epub 2005 Dec 22.

Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.

Int J Clin Pract. 2007 Jul;61(7):1234-5; author reply 1235. doi: 10.1111/j.1742-1241.2007.01399.x.

Spotlight on agalsidase beta in Fabry disease.

BioDrugs. 2007;21(4):269-71. doi: 10.2165/00063030-200721040-00007.

引用本文的文献

Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down-Regulation of Mannose-6-Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy.

J Am Heart Assoc. 2025 Feb 18;14(4):e036815. doi: 10.1161/JAHA.124.036815. Epub 2025 Feb 8.

Fabry disease: A pharmacological chaperone on the horizon.

Nat Rev Nephrol. 2016 Nov;12(11):653-654. doi: 10.1038/nrneph.2016.138. Epub 2016 Sep 26.

Fabry disease, enzyme replacement therapy and the significance of antibody responses.

J Inherit Metab Dis. 2012 Mar;35(2):227-43. doi: 10.1007/s10545-011-9400-y. Epub 2011 Oct 25.

Fabry disease.

Orphanet J Rare Dis. 2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30.

Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

J Control Release. 2011 Feb 10;149(3):323-31. doi: 10.1016/j.jconrel.2010.10.031. Epub 2010 Nov 1.

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Biologics. 2008 Dec;2(4):823-43. doi: 10.2147/btt.s3770.

Medical bioremediation of age-related diseases.

Microb Cell Fact. 2009 Apr 9;8:21. doi: 10.1186/1475-2859-8-21.

Fabry disease in children and the effects of enzyme replacement treatment.

Eur J Pediatr. 2009 Nov;168(11):1355-63. doi: 10.1007/s00431-009-0937-9. Epub 2009 Feb 26.

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献